DSGN - Company ID 0001807120
The table below shows Design Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$16.43M | -$16.79M | -$12.44M | -$17.42M | -$11.83M | -$3.70M |
| Capital expenditure | $0.00 | $72.00K | $195.00K | $87.00K | $76.00K | $33.00K |
| Investing cash flow | -$7.59M | $7.87M | $20.62M | $19.73M | $414.00K | $23.03M |
| Dividends paid | - | - | - | - |
Design Therapeutics, Inc. reported operating cash flow of -$54.36M for fiscal year 2025. That is down 26.1% from -$43.10M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$8.67M (FY 2020) to -$54.36M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $19.93M | $23.00K | $20.00K | - | $156.00K | $378.98M |